Blackstone Life Sciences (BXLS) fills a critical void in the industry. While life sciences is seeing unprecedented innovation driven by rapid advancements in science and technology, it often lacks the necessary funding to bring medicines and healthcare technologies to market. We work in partnership with the pharmaceutical, biotechnology and medical technology industries to help meet this need.
In 2018, Blackstone acquired Clarus, a leading global life sciences firm. Blackstone Life Sciences combines Clarus’ scientific and clinical development expertise with Blackstone’s knowledge and global network, access to capital, resources and infrastructure. We commit our skill and scale to select, fund and advance what we believe to be the most promising life science products through hands-on involvement and directly applied expertise.
We seek to deliver value for investors within the life sciences industry by focusing on areas where we can apply our deep commercial and clinical domain expertise. We make private investments mostly in products rather than companies, with a focus on the most promising candidates in late-stage development. Our priority is to have the greatest positive impact on the most people with the lowest clinical risk and the highest probability of success.
All numbers are as of December 31, 2019.
*Includes medicines brought to market by BXLS, development company employees and advisors (Nick Galakatos, Emmett Cunningham, Kurt Wheeler, Bob DeBenedetto, Barry Gertz, Dennis Henner, Ed Scolnick, Jeff Chodakewitz) while they worked at prior employers. The development of a medicine involves many professionals. The degree of involvement by a given professional varies medicine to medicine. Therefore, the performance shown reflects the contributions of a number of professionals and may not be indicative of any individual's contributions to the transactions. Senior Advisors are not employees of Blackstone.